8-KItem 5.02 · Officer/Director ChangeItem 7.01 · Reg FD DisclosureItem 9.01 · Financial Statements

Labcorp ($LH) appointed John H.

Filed with the SEC on · Summarized by InvestorsBot

Labcorp ($LH) appointed John H. Sampson, M.D., Ph.D. to its Board (announced Feb 6; effective Feb 9, 2026) and named him to the Quality & Compliance Committee. Director compensation per proxy filed Apr 4, 2025. 🧑‍⚕️ #CorporateGovernance #Healthcare

Dr. Sampson is vice chancellor for health affairs & dean at UC Anschutz School of Medicine; formerly senior VP at Duke Health. Practicing neurosurgeon, Natl Academy of Medicine member, ~300 peer‑reviewed publications. 🧠 $LH #LifeSciences #Research

Appointment adds substantial clinical and research expertise to Labcorp’s Quality & Compliance oversight. No special equity or unique compensation disclosed; he will be paid under Labcorp’s standard director program. 📈 $LH #Labcorp #Healthcare

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from LABCORP HOLDINGS INC.